Background Achieving the greatest reduction in atherogenic lipoproteins requires the
optimum dose and potency of statin. Using data from the VOYAGER meta-analysis, we …

Introduction. Cardiovascular diseases are the leading cause of death worldwide. The
combination of statins and cholesterol‐absorption inhibitors promotes the decrease in risk …

Lipid-lowering guidelines continue to evolve toward the use of (1) global risk assessment,(2)
lipid measures other than or in addition to low-density lipoprotein (LDL) cholesterol in …

Background: Statins have emerged as the global leader in pharmacologic therapy for
dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in …

OBJECTIVE: Guidelines published in 2011 by the European Atherosclerosis Society and the
European Society of Cardiology recommend a goal of either low-density lipoprotein …

Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …

Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis
of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A …

Background Data from Western comparative trials suggest that rosuvastatin is more effective
than atorvastatin, simvastatin, and pravastatin in helping hypercholesterolemic patients …

Background Rosuvastatin has been claimed to be more potent than other statins in its ability
to lower the low-density lipoprotein (LDL) cholesterol levels. This study aimed to investigate …

Background There is no randomized clinical trials with recurrence of atherosclerotic
cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze …